Tesofensine: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 7 sources cited
Overview
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, and dopamine) originally developed for Alzheimer's and Parkinson's disease that was repurposed for obesity treatment after clinical trials revealed dramatic weight loss as a side effect. It is one of the most potent appetite suppressants studied in clinical trials, with Phase II data showing about 9% weight loss at 0.5 mg and 10.6% at 1.0 mg over 24 weeks, roughly twice what drugs approved at the time achieved.
Mechanism of Action
Tesofensine inhibits the reuptake of three key monoamine neurotransmitters — serotonin (5-HT), norepinephrine (NE), and dopamine (DA) — by blocking their respective transporters (SERT, NET, DAT). This triple reuptake inhibition produces a multifaceted appetite-suppressive effect: serotonin elevation reduces hunger and promotes satiety via hypothalamic 5-HT2C receptors, norepinephrine increases sympathetic tone and thermogenesis while reducing appetite via α1 receptors, and dopamine modulates the reward circuitry to reduce hedonic eating. The dopamine component is what distinguishes tesofensine from SSRIs or SNRIs — by reducing the drive to eat for pleasure (not just hunger), it addresses a major contributor to obesity. The effect on energy expenditure in people is smaller than the appetite effect: a 2-week study in overweight men found no significant change in 24-hour energy expenditure, with night-time expenditure 4.6% higher and 24-hour fat oxidation increased.
Tesofensine Benefits: What the Research Shows
- Phase II trial (2008, Lancet, n=203, NCT00394667): the 0.5 mg dose with an energy restricted diet produced 9.2% weight loss against 2.0% on diet plus placebo over 24 weeks, which the authors said was about twice the loss seen with drugs approved at the time
- The 1.0 mg dose produced 10.6% weight loss but with more side effects
- In a separate 2-week study in overweight men, tesofensine did not significantly change 24-hour energy expenditure; night-time expenditure was 4.6% higher and 24-hour fat oxidation rose by 18 g, alongside higher ratings of satiety and fullness
- Heart rate increased by an average of 7.4 bpm, the main safety signal
- Blood pressure was not significantly affected at the 0.5 mg dose
- Saniona has taken the combination Tesomet (tesofensine plus metoprolol, to offset the heart rate rise) through phase 1 and phase 2 trials in hypothalamic obesity and Prader-Willi syndrome; two registered phase 2 studies were withdrawn in 2021 for financial reasons, and the drug remains under regulatory review
Tesofensine Dosage
- Phase II trial doses: 0.25 mg, 0.5 mg, or 1.0 mg orally once daily
- The 0.5 mg dose showed the best efficacy-to-side-effect ratio in trials
- Take in the morning to avoid insomnia due to noradrenergic/dopaminergic stimulation
- No food timing restrictions for oral administration
- Typical cycle: 8–24 weeks based on Phase II trial durations
- Dose escalation from 0.25 mg for the first week may reduce initial side effects
- Half-life is about 234 hours, roughly 10 days, so several weeks of daily dosing are needed to reach steady state
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Tesofensine Side Effects & Safety
Known Side Effects
- Increased heart rate (5–8 bpm on average) — the primary safety concern and reason for development delays
- Dry mouth, the most frequently reported adverse event in the phase II obesity trial
- Insomnia and difficulty sleeping, especially at higher doses or with late-day dosing
- Constipation and gastrointestinal discomfort
- Headache and dizziness in the first 1–2 weeks
- Mood changes including anxiety or irritability (monoaminergic stimulation)
- Potential for abuse/dependence due to dopamine reuptake inhibition, though clinical data has not shown this
Safety Profile
Tesofensine's primary safety concern is cardiovascular — the heart rate increase of 5–8 bpm observed in trials prompted regulatory caution and contributed to development delays. This effect is attributed to norepinephrine reuptake inhibition increasing sympathetic tone. The combination product Tesomet pairs tesofensine with metoprolol (a beta-blocker) to specifically mitigate this issue. Blood pressure effects have been modest and not clinically significant. The dopamine reuptake inhibition raises theoretical addiction concerns, but clinical trials have not demonstrated abuse liability or withdrawal symptoms. Psychiatric monitoring is advisable given the monoaminergic mechanism. Tesofensine should not be combined with MAO inhibitors, SSRIs, or other serotonergic drugs due to serotonin syndrome risk. Not recommended in patients with uncontrolled hypertension, cardiac arrhythmias, or history of substance abuse.
What to Expect
Week 1–2: Appetite reduction is noticeable within days due to rapid monoamine effects. Some stimulant-like feelings — increased alertness, mild euphoria. Dry mouth is common. Potential for mild insomnia. Week 2–4: Appetite suppression becomes pronounced. Food portions decrease naturally. Weight loss begins (2–4 lbs). Heart rate may be slightly elevated. Dry mouth typically persists. Week 4–12: Steady weight loss of 1–2 lbs per week. Steady state is reached. Appetite is consistently reduced. Energy levels are generally improved. Side effects tend to stabilize or improve. Week 12–24: In the phase II trial, mean weight loss over 24 weeks was 9.2% at 0.5 mg and 10.6% at 1.0 mg, on top of an energy restricted diet. Metabolic markers improve. Body composition changes become visually apparent. Cravings for hyperpalatable foods significantly diminish.
Common Stacks
Semaglutide
GLP-1 receptor agonism provides complementary appetite suppression through peripheral (gut/pancreas) mechanisms while tesofensine works centrally, potentially producing additive weight loss
AOD-9604
AOD-9604 promotes lipolysis without CNS effects, complementing tesofensine's central appetite suppression with direct fat metabolism enhancement
Storage & Handling
Store tesofensine capsules/tablets at room temperature (15–25°C) in a sealed container, protected from light and moisture. Shelf life is approximately 2–3 years when properly stored. No reconstitution required for oral formulations.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008.
- Sjödin A, Gasteyger C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010.
- Lehr T, Staab A, Tillmann C, et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol. 2007.
- Rascol O, Poewe W, Lees A, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol. 2008.
- Krug O, Thomas A, Thevis M. Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine. Drug Test Anal. 2026.
- Registered studies of Tesomet. ClinicalTrials.gov. 2026.
- Registered studies of tesofensine. ClinicalTrials.gov. 2026.
Related Peptides
Track Tesofensine in Your Protocol
Log your Tesofensine doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free